PDO (POLYDIOXANONE) MONOFILAMENT SYNTHETIC ABSORBABLE SUTURE U.S.P.

K022666 · Arc Medical Supplies (Beijing) Co, Ltd. · NEW · Oct 9, 2002 · General, Plastic Surgery

Device Facts

Record IDK022666
Device NamePDO (POLYDIOXANONE) MONOFILAMENT SYNTHETIC ABSORBABLE SUTURE U.S.P.
ApplicantArc Medical Supplies (Beijing) Co, Ltd.
Product CodeNEW · General, Plastic Surgery
Decision DateOct 9, 2002
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 878.4840
Device ClassClass 2
AttributesTherapeutic, Pediatric

Intended Use

PDO (Polydioxanone) Monofilament Synthetic Absorbable Sutures U.S.P. are indicated for use in general soft tissue approximation and/or ligation, including use in pediatric cardiovascular tissue where growth is expected to occur and ophthalmic surgery. PDO is not indicated for use in adult cardiovascular tissue, microsurgery and neural tissue. These sutures are useful where an absorbable suture with extended wound support (up to six weeks) is desirable.

Device Story

Monofilament synthetic absorbable suture composed of Poly(p-dioxanone) acid; un-dyed or dyed with D&C Violet No. 2. Used by surgeons for soft tissue approximation and ligation. Provides extended wound support for up to six weeks. Device is sterile, single-use surgical material.

Clinical Evidence

Bench testing only. Testing performed according to U.S.P. XXIII methods for suture diameter, length, knot pull tensile strength, needle attachment strength, and absorption rate. Results demonstrate that the device meets or exceeds U.S.P. specifications and is equivalent to the predicate.

Technological Characteristics

Monofilament synthetic absorbable suture; material: Poly(p-dioxanone) acid; color: un-dyed or D&C Violet No. 2; performance standards: U.S.P. XXIII; sterilization: not specified.

Indications for Use

Indicated for general soft tissue approximation and/or ligation, including pediatric cardiovascular tissue (where growth is expected) and ophthalmic surgery. Contraindicated for adult cardiovascular tissue, microsurgery, and neural tissue.

Regulatory Classification

Identification

An absorbable polydioxanone surgical suture is an absorbable, flexible, sterile, monofilament thread prepared from polyester polymer poly (p-dioxanone) and is intended for use in soft tissue approximation, including pediatric cardiovascular tissue where growth is expected to occur, and ophthalmic surgery. It may be coated or uncoated, undyed or dyed, and with or without a standard needle attached.

Special Controls

*Classification.* Class II (special controls). The special control for the device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Kozz b.i.^{24}_{6} # ARC Medical Supplies(Beijing) Co., Ltd. OCT 0 9 2002 #66 Qian Ban Bi Jie, Xizhirnen Nei, Beijing CHINA 100035 Tel: 8610-6617 8581 Fax: 8610-66113481 Email: arcmedic@public.bta.net.cn Page 1 of 2 ## 510(k) SUMMARY This summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92 The assigned 510(k) number is: _______________________________________________________________________________________________________________________________________________ | Applicant | ARC Medical Supplies (Beijing) Co., Ltd.<br>#66 Quian Ban Bi Jie, Xizhimen Nei<br>Beijing, China 100035<br>Telephone: 8610 6617 8581<br>Fax: 8610 6611 3481 | |-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Contact Person | Mr. Charles F. Andrews<br>C.F. Andrews & Associates<br>1591 S. Moorland Road, Suite 104<br>New Berlin, WI 53151<br>Telephone: (414) 416-9119<br>Fax: (414) 389-1650 | | Date | August 7, 2002 | | Name of Device | | | Proprietary Name: | PDO (Polydioxanone) Monofilament<br>Synthetic Absorbable Suture U.S.P. | | Common or Usual Name: | Polydioxanone Monofilament<br>Synthetic Absorbable Suture U.S.P. | | Classification Name: | Suture, Absorbable, Synthetic, Polydioxanone | {1}------------------------------------------------ Korticki ## ARC Medical Supplies(Beijing) Co., Ltd. #66 Qian Ban Bi Jie, Xizhimen Nei, Beijing CHINA 100035 Tel: 8610-6617 8581 Fax: 8610-66113481 Email: arcmedic@public.bta.net.cn Page 2 of 2 #### 510(k) SUMMARY - continued Monofilament Synthetic Absorbable Sutures. PDO (Polydioxanone) U.S.P. manufactured by ARC Medical Supplies (Beijing) Co., Ltd. are equivilent to MONO-DOX synthetic absorbable polydioxanone surgical sutures manufactured by CP Medical. The PDO (Polydioxanone) Monofilament Synthetic Absorbable Sutures, U.S.P. manufactured by ARC Medical and CP Medical are monofilament suture composed of a Poly(p-dioxanone) acid, un-dyed or dyed with D&C Violet No. 2. PDO (Polydioxanone) Monofilament Synthetic Absorbable Sutures are indicated for use in general soft tissue approximation and/or ligation, including use in pediatric cardiovascular tissue where growth is expected to occur and ophthalmic surgery. PDO is not indicated for use in adult cardiovascular tissue, microsurgery and neural These sutures are useful where an absorbable suture with extended wound tissue. support (up to six weeks) is desirable. Testing of suture diameter, suture length, knot pull tensile strength, needle attachment strength and absorption rate according to methods outlined in U.S.P. XXIII demonstrates that ARC Medical PDO (Polydioxanone) Monofilament Synthetic Absorbable sutures meet or exceed U.S.P. specifications and are equivalent in terms of the above parameters to Synthetic Absorbable polydioxanone surgical sutures manufactured by CP Medical. K Richard Kuo, Chairman P-L-Q I Date {2}------------------------------------------------ ### DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 ARC Medical Supplies (Beijing) Co., Ltd. c/o Mr. Charles F. Andrews President C.F. Andrews & Associates 1591 S. Moorland Road, Suite 104 New Berlin, Wisconsin 53151 ## OCT 0 9 2002 Re: K022666 Trade/Device Name: PDO (Polydioxanone) Monofilament Synthetic Absorbable Suture Regulation Number: 21 CFR 878.4840 Regulation Name: Suture, surgical, absorbable, polydioxanone Regulatory Class: Class II Product Code: NEW Dated: August 29, 2002 Received: August 30, 2002 Dear Mr. Andrews: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ Page 2 - Mr. Charles F. Andrews This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Styt Rlvelu Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ KO2266 ### 510(k) Number : K022666 Device Name: PDO (Polydioxanone) Monofilament Synthetic Absorbable Suture U.S.P. Indications for Use: PDO (Polydioxanone) Monofilament Synthetic Absorbable Sutures U.S.P. are indicated for use in general soft tissue approximation and/or ligation, including use in pediatric cardiovascular tissue where growth is expected to occur and ophthalmic surgery. PDO is not indicated for use in adult cardiovascular tissue, microsurgery and neural tissue. These sutures are useful where an absorbable suture with extended wound support (up to six weeks) is desirable. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Styp Purcle (Division Sign-Off) Division of General, Restorative and Neurological Devices 510(k) Number K022666
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%